Natco Pharma Limited (NATCOPHARM) Share Price, Dividend & Analysis | Anvest

AI Company ProfileSign in to generate AI briefing

AI Snapshot

Natco Pharma Limited is a pharmaceutical company focused on providing innovative and green chemistry-based crop solutions. It offers pesticides, insecticides, and herbicides to farmers, aiming to increase crop yields.

Drug Manufacturers - Specialty & GenericFounded:1981CEO/MD:Rajeev NannapaneniHQ:Hyderabad, Telangana

Business profile as of 2026-08-25

Business at a Glance

Natco Pharma's Agrochemicals Business division focuses on developing and supplying pesticides, insecticides, herbicides, and bio-stimulants.
The company emphasizes the application of safety learnings in its daily operations.

Revenue growth: -7.9%FY26 growth+14.6%3Y CAGR
EPS growth: -24.8%FY26 growth+26.4%3Y CAGR
CFO / PAT: 1.25×FY26

What Looks Strong

GrowthRevenue grew at +14.6% CAGR over three years.
Cash FlowOperating cash flow was 1.25× total net profit in FY26.
ValuationTrailing P/E is 12.2×. The valuation score is 79/100.

What to Watch

RevenueRevenue declined about 8% in FY26 (consolidated: ₹4,430 cr → ₹4,078 cr). Watch whether the next results confirm a trend or a one-off.
EarningsNet profit fell about 25% in FY26 (consolidated: ₹1,885 cr → ₹1,418 cr). Watch margins and one-off items in the next filing.
MarginsOperating margin compressed from ~44.3% to ~30.2% in FY26 (consolidated). Watch input costs and pricing in the next two results.
TrendPrice is 16% below its 200-day moving average, indicating a weak long-term price trend.

Segment revenue, FY26 (consolidated, as filed): Pharmaceuticals 97%; Agro chemicals 3%.
Share of segment profit before interest and tax, FY26: Pharmaceuticals 100%. Agro chemicals made a segment loss of ₹19.8 cr.
Natco Pharma generates revenue by researching, developing, manufacturing, and selling complex generic and specialty pharmaceutical formulations and active pharmaceutical ingredients (APIs).

FY26 (consolidated): revenue ₹4,078 cr, down 8% from ₹4,430 cr in FY25; net profit ₹1,418 cr, down 25% from ₹1,885 cr in FY25.
FY26 (consolidated): operating cash flow ₹1,768 cr (1.2× net profit); debt/equity 0.08×.
Latest quarter to Jun 2026 (consolidated): revenue ₹735 cr (down 45% year on year); net profit ₹206 cr.

The Agrochemicals Business division accounted for 1.48% of the company's total turnover in the financial year ending March 31, 2025,…